


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:	CERTIFICATE UNDER 37 C.F.R. 1.8(a)
Caput et al.	I hereby certify that this correspondence is being
Serial No.: 09/125,005	deposited on the date indicated below with the
Filed: July 30, 1998	United States Postal Service as first class mail
Group Art Unit: 1643	addressed to: Box Sequence, Assistant
Examiner: Ungar, S.	Commissioner for Patents,
For: Purified SR-p70 Protein	Washington, DC 20231
	Name: <i>Kathy Smith Dias</i>
	Date: <i>1/21/00</i>



Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING"
UNDER 37 CFR 1.821

Dear Sir:

This is in response to the Office communication (paper no. 4) mailed October 1, 1999. In light of a three-month extension of time and fee therefor enclosed herewith, response is due by February 1, 2000; this response is, therefore, timely filed.

Enclosed are (1) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; (2) a computer readable copy of the Sequence Listing for the above-identified application; and (3) a paper copy of the "Sequence Listing"; (4) an amendment directing its entry into the specification and (5) a statement that the computer readable copy and substitute paper copy of the sequence listing are the same.

Respectfully submitted,

Date: *1/21/00*

Kathy Smith Dias
Kathy Smith Dias
Reg. No. 41,707

Address:
Patent Department
Sanofi Pharmaceuticals, Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Tele: (610) 889-8802
Fax: (610) 889-8799

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Caput et al.

Serial No.: 09/125,005

Filed: July 30, 1998

Group Art Unit: 1643

Examiner: Ungar, S.

For: Purified SR-p70 Protein



CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, DC 20231

Name

Kathy Smith Dias

Date

1/21/00

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR 1.821(f) and(g)

Dear Sir:

Applicants' undersigned representative states that the content of the sequence listing, pages 1-48, of the above-captioned patent application and the computer readable copy filed herewith on computer disk are the same and that the computer readable copy includes no new matter.

Respectfully submitted,

Date:

1/21/00

Address:
Patent Department
Sanofi Pharmaceuticals, Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Tele: (610) 889-8802
Fax: (610) 889-8799

Kathy Smith Dias

Kathy Smith Dias
Reg. No. 41,707

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.